

Andreas Schildan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10157877/publications.pdf>

Version: 2024-02-01

29
papers

874
citations

516710

16
h-index

526287

27
g-index

35
all docs

35
docs citations

35
times ranked

1053
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of ¹⁸ F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	9.0	145
2	Decreased cerebral $\alpha 4\beta 2^*$ nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 515-525.	6.4	109
3	Individualized quantification of brain $\beta 2$ -amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1702-1714.	6.4	91
4	Evaluation of early-phase [¹⁸ F]-florbetaben PET acquisition in clinical routine cases. NeuroImage: Clinical, 2017, 14, 77-86.	2.7	91
5	In vivo measurement of nicotinic acetylcholine receptors with [¹⁸ F]norchloro-fluoro-homoepibatidine. Synapse, 2008, 62, 205-218.	1.2	47
6	Cortical [¹⁸ F]-PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
7	Early-phase [¹⁸ F]-PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
8	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
9	Binding characteristics of [¹⁸ F]-PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2957-2972.	4.3	30
10	Metabolite analysis of [¹⁸ F]-Florbetaben (BAY 94-9172) in human subjects: a substudy within a proof of mechanism clinical trial. Journal of Radioanalytical and Nuclear Chemistry, 2010, 284, 557-562.	1.5	28
11	Norchloro-fluoro-homoepibatidine (NCFHEB) – A promising radioligand for neuroimaging nicotinic acetylcholine receptors with PET. European Neuropsychopharmacology, 2008, 18, 222-229.	0.7	25
12	Measurement of the $\alpha 4\beta 2^*$ nicotinic acetylcholine receptor ligand 2-[¹⁸ F]-Fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study. Nuclear Medicine and Biology, 2007, 34, 331-342.	0.6	22
13	Feasibility of short imaging protocols for [¹⁸ F]-PI-2620 tau-PET in progressive supranuclear palsy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3872-3885.	6.4	22
14	Fully automated radiosynthesis of both enantiomers of [¹⁸ F]-Flubatine under GMP conditions for human application. Applied Radiation and Isotopes, 2013, 80, 7-11.	1.5	20
15	Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (α)-[¹⁸ F]-Flubatine in humans. Nuclear Medicine and Biology, 2014, 41, 489-494.	0.6	18
16	Internal Dose Assessment of (α)- ¹⁸ F-Flubatine, Comparing Animal Model Datasets of Mice and Piglets with First-in-Human Results. Journal of Nuclear Medicine, 2014, 55, 1885-1892.	5.0	17
17	Radiation dosimetry of the $\alpha 4\beta 2$ nicotinic receptor ligand (+)-[¹⁸ F]-flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results. EJNMMI Physics, 2016, 3, 25.	2.7	17
18	Synthesis procedure for routine production of 2-[¹⁸ F]-fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸ F]-F-A-85380). Applied Radiation and Isotopes, 2007, 65, 1244-1248.	1.5	16

#	ARTICLE	IF	CITATIONS
19	Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2239-2248.	6.4	15
20	Binding properties of the cerebral $\alpha 4\beta 2$ nicotinic acetylcholine receptor ligand 2-[¹⁸ F]fluoro-A-85380 to plasma proteins. <i>Nuclear Medicine and Biology</i> , 2006, 33, 899-906.	0.6	12
21	Autoradiography of 2-[¹⁸ F]F-A-85380 on nicotinic acetylcholine receptors in the porcine brain in vitro. <i>Synapse</i> , 2006, 59, 201-210.	1.2	11
22	¹⁸ F- and ¹¹ C-labelling of quantum dots with n.c.a. [¹⁸ F]fluoroethyltosylate and [¹¹ C]methyl iodide: a feasibility study. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2010, 283, 487-491.	1.5	10
23	Synthesis and evaluation of tritium labelled 10-methylgalanthamine iodide: a novel compound to examine the mechanism of interaction of galanthamine derivatives with the nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 1117-1125.	1.0	3
24	ICP-MS: ¹⁸ F-PI2620 TAU-PET IN PROGRESSIVE SUPRANUCLEAR PALSY: A MULTI-CENTER EVALUATION. <i>Alzheimer's and Dementia</i> , 2019, 15, P128.	0.8	3
25	Influence of additives to the formulation of n.c.a. [¹¹ C]PiB on sterile filter performance. <i>Applied Radiation and Isotopes</i> , 2013, 82, 289-292.	1.5	2
26	Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
27	Lower cortical Alpha4Beta2 nicotinic acetylcholine receptor binding and its relationship to cognitive dysfunction in early stage multiple sclerosis: A 2-[¹⁸ F]F-A-85380 PET study. <i>NeuroImage</i> , 2010, 52, S111.	4.2	0
28	Nicotinic acetylcholine receptors in patients with Parkinson's disease and Alzheimer's disease: Specific binding of 2-[¹⁸ F]F-A-85380 in the cerebral white matter as demonstrated by PET and comparison with diffusion tensor MRI (DTI). <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S584-S584.	4.3	0
29	Feasibility of short imaging protocols for [¹⁸ F]PI2620 tau-PET in progressive supranuclear palsy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0